

DEC 20 2006

Serial No. 10/049,608
Docket No. 3828-4000US2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-64. (cancelled)

65. (new) A method of detecting ovarian cancer in a patient comprising:

- a) obtaining a sample of body fluid from the patient;
- b) contacting the sample with a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450 or an antigen binding fragment thereof; and
- c) detecting a complex formed by the monoclonal antibody bound to its antigen, wherein detection of the complex in the biological sample in an amount greater than an amount of the complex in a normal sample of body fluid indicates the presence of ovarian cancer.

66. (new) The method of claim 65 wherein the sample is contacted with the antigen binding fragment of the monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450.

67. (new) The method of claim 66 wherein the antigen binding fragment is an F(ab')₂, Fab', Fv, Fd', or Fd.

Serial No. 10/049,608
Docket No. 3828-4000US2

68. (new) The method of claim 65 further comprising labeling the monoclonal antibody or fragment thereof with a detectable moiety.

69. (new) The method of claim 68 wherein the detectable moiety is a fluorophore, a chromophore, a radionuclide, or an enzyme.

70. (new) The method of claim 65 wherein the body fluid is blood, serum, or plasma.

71. (new) A method of detecting ovarian cancer in a patient comprising:

- a) obtaining a sample of body fluid from the patient; and
- b) measuring in the sample of body fluid a level of an antigen that is bound to by a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC[®]) as ATCC Accession Number PTA-450, wherein the antigen
 - (i) is a single polypeptide with a molecular weight of about 76 kDa to about 213 kDa as determined by SDS PAGE under reducing conditions;
 - (ii) is absent from human peripheral blood mononuclear cells, human B cells, and human B cell myelogenic leukemia cells; and
 - (iii) is glycosylated,

wherein detection of the antigen in the biological sample in an amount greater than an amount of the antigen in a normal sample of body fluid indicates the presence of ovarian cancer.

Serial No. 10/049,608
Docket No. 3828-4000US2

72. (new) The method of claim 71 wherein the antigen is detected by a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450 or an antigen binding fragment thereof.

73. (new) The method of claim 72 wherein the antigen binding fragment is an F(ab')₂, Fab', Fv, Fd', or Fd.

74. (new) The method of claim 71 further comprising labeling the monoclonal antibody or fragment thereof with a detectable moiety.

75. (new) The method of claim 74 wherein the detectable moiety is a fluorophore, a chromophore, a radionuclide, or an enzyme.

76. (new) The method of claim 71 wherein the body fluid is blood, serum, or plasma.